[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369599-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369599-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","unveiling-the-anticancer-potential-of-sglt-2-inhibitors-mechanisms-and-prospects-in-clinical-oncology-a-narrative-review","Unveiling the anticancer potential of SGLT-2 inhibitors - mechanisms and prospects in clinical oncology - a narrative review","","Recent years have seen cancer become more common among younger populations, intensifying public-health and economic burden. Many current cancer therapies remain costly and require long development cycles. Sodium-glucose cotransporter-2 inhibitors (SGLT-2is), initially developed for blood-glucose control, show anticancer promise by restricting glucose uptake in tumor cells and thereby limiting energy for growth. Evidence in lung and hepatocellular cancers indicates reduced tumor volume and suppressed metastasis via pathway modulation (e.g., AMPK/mTOR, HIF-1α), while improving chemotherapy and immunotherapy efficacy. Diabetes mellitus increasingly overlaps with cancer, adding urgency to clarify mechanistic links and explore synergistic combination strategies across tumor types.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/unveiling-the-anticancer-potential-of-sglt-2-inhibitors-mechanisms-and-prospects-in-clinical-oncology-a-narrative-review/369599/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/unveiling-the-anticancer-potential-of-sglt-2-inhibitors-mechanisms-and-prospects-in-clinical-oncology-a-narrative-review/369599.png","ImageObject",300,407,{"name":42,"@type":43},"Melati","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How do SGLT-2 inhibitors potentially inhibit tumor growth?","Question",{"text":63,"@type":64},"They inhibit glucose uptake in tumor cells, limiting the energy supply required for tumor growth. This mechanism is linked to downstream modulation of key signaling pathways.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What evidence is described for SGLT-2 inhibitors in specific cancer types?",{"text":68,"@type":64},"The document cites findings in lung and hepatocellular cancers, reporting reduced tumor volume and suppressed metastasis through pathway regulation such as AMPK/mTOR and HIF-1α.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is diabetes mellitus (DM) relevant to anticancer treatment strategies here?",{"text":72,"@type":64},"DM increasingly affects younger populations and overlaps with cancer, with patients facing higher cancer risks for liver, colorectal, and pancreatic cancers. The document highlights the need to integrate both conditions when designing treatments.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369599,1790893292,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Li etal. European Journal of Medical Research (2025) 30:520  \n[https://doi.org/10.1186/s40001-025-02749-3](https://doi.org/10.1186/s40001-025-02749-3)  \nEuropean Journal of Medical Research  \n REVIEW Open Access  \nUnveiling the anticancer potential of SGLT-2   inhibitors: mechanisms and prospects in clinical oncology—a narrative review  \nJiaxin Li1†, Jie Qiao2†, Shitong Zhang3, Jianhua Zhong1, Caiying Ke1, Yiqi Lin1, Yuetong Li1, Ying Jin1, Yaqi Yao1, Aixia Zhai2* and Changlong Bi 1*  \nAbstract  \nIn recent years, cancer has become more prevalent among younger populations, increasing the burden on public health and the economy. Current cancer treatments are often costly and have long trial periods. Sodium-glucose cotransporter-2 inhibitors (SGLT-2is), including dapagliflozin and canagliflozin, were originally developed for blood glucose control, but have shown promise in anticancer applications. These inhibitors work by inhibiting glucose uptake in tumor cells, thus limiting the energy supply needed for tumor growth. For instance, in lung and hepatocellular cancers, SGLT-2is have been demonstrated to reduce tumor volume and suppress metastasis by modulating key signaling pathways, such as AMPK/mTOR and HIF-1α . Additionally, their ability to enhance the efficacy of chemotherapy and immunotherapy further underscores their potential in cancer treatment. Numerous studies have been conducted on this topic. Diabetes mellitus (DM) is increasingly affecting younger populations and overlaps significantly with cancer. DM patients face higher cancer risks, particularly for liver, colorectal, and pancreatic cancers, with studies indicating up to a 20% increased risk. This highlights the need to consider both conditions in treatment strategies and understand the mechanisms linking DM and cancer to improve outcomes. This study explores the relationship between SGLT-2is and cancer, focusing on their mechanisms in various tumor types and their synergistic effects in combination with other therapies. In the current study, we determined the relationship between SGLT-2is and cancer, and elaborated on the role and mechanisms of SGLT-2is in tumors at different primary sites. In addition, we introduced the anti-tumor effects of SGLT-2is in combination with other means and the underlying mechanisms. From the single-operator to combined-operator level, we reveal the prospects of SGLT-2is in clinical oncology and the future outlook.  \nKeywords SGLT-2 inhibitors, Anticancer, Mechanisms, Synergistic anti-tumor effects  \n†Jiaxin Li and Jie Qiao have contributed equally to this work.  \n*Correspondence: Aixia Zhai  \n[aixiazhai@126.com](aixiazhai@126.com); [zhaiaix@mail.sysu.edu.cn](zhaiaix@mail.sysu.edu.cn)  \nChanglong Bi  \n[BCL163@163.com](BCL163@163.com); [bichlong@mail.sysu.edu.cn](bichlong@mail.sysu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4","cbCaib0fFnQV5q2D","https://ap.wps.com/l/cbCaib0fFnQV5q2D","pdf",1310160,"English","# Introduction\n## Rationale for new targeted, cost-effective anticancer strategies\n# Abstract\n## Anticancer mechanisms of SGLT-2 inhibitors\n## Role in diabetes-cancer overlap and combination therapy","[{\"question\":\"How do SGLT-2 inhibitors potentially inhibit tumor growth?\",\"answer\":\"They inhibit glucose uptake in tumor cells, limiting the energy supply required for tumor growth. This mechanism is linked to downstream modulation of key signaling pathways.\"},{\"question\":\"What evidence is described for SGLT-2 inhibitors in specific cancer types?\",\"answer\":\"The document cites findings in lung and hepatocellular cancers, reporting reduced tumor volume and suppressed metastasis through pathway regulation such as AMPK/mTOR and HIF-1α.\"},{\"question\":\"Why is diabetes mellitus (DM) relevant to anticancer treatment strategies here?\",\"answer\":\"DM increasingly affects younger populations and overlaps with cancer, with patients facing higher cancer risks for liver, colorectal, and pancreatic cancers. The document highlights the need to integrate both conditions when designing treatments.\"}]","Unveiling the anticancer potential of SGLT-2 inhibitors - mechanisms and prospects in clinical oncology - a narrative review | PDF",1790183625,48,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/54ece983e963cefa2da5ddc42600d26b.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a97c1cf0e988311ca64f4ec4b377c40a.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3837b835e4c88a6ab7943fef2cba6ca3.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0c964b57cb5ccaa94f667d627c2ecf7.webp",980,1301]